Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292534 · ClinicalTrials.gov registry record · NA
Evaluation of the Clinical Benefit of the Hearing Aids Tinnitus Feature.
A NA study, sponsored by Sonova.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT05292534: Completed NA study, sponsored by Sonova.
NCT05292534 is a NA study that has completed, run by Sonova. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05292534, a NA study, has completed, sponsored by Sonova.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Participants with hearing loss and Tinnitus will wear hearing aids with amplification-only or with an added sound, and have their tinnitus level evaluated before and after intervention.
Primary Outcome
Tinnitus Functional Index (TFI) questionnaire results, ranging from 0 to 100, with higher numbers indicating more severe (worse) Tinnitus interference in the person's quality of life.
Interventions
- DEVICE hearing aid amplification
- DEVICE hearing aid amplification with an added sound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-09-20 |
| Phase | NA |
What the finished NCT05292534 record still lists
NCT05292534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which hearing aid amplification is the first listed.
NCT05292534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05292534 about?
NCT05292534 is a clinical study titled "Evaluation of the Clinical Benefit of the Hearing Aids Tinnitus Feature.". Participants with hearing loss and Tinnitus will wear hearing aids with amplification-only or with an added sound, and have their tinnitus level evaluated before and after intervention.
What is the current status of trial NCT05292534?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2022-06-01. Estimated completion is 2023-09-20.
What interventions are being tested in trial NCT05292534?
The interventions under investigation include: hearing aid amplification (DEVICE), hearing aid amplification with an added sound (DEVICE).
Who is sponsoring clinical trial NCT05292534?
This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05292534's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI